Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL. By admin / 06/01/2016
Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. By admin / 06/01/2016
Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab By admin / 06/01/2016
Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor. By admin / 04/16/2016
Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas. By admin / 12/08/2015
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. By admin / 12/08/2015
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia. By admin / 12/08/2015
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia. By admin / 12/08/2015
Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/20/2015
Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies. By admin / 06/20/2015
